Is BIO a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Bio-Rad Laboratories (BIO) rests on Sartorius stake and activist pressure: Bio-Rad's roughly 28% holding in Sartorius is worth close to its entire market value, so movements in that German stock swing Bio-Rad's book value and sentiment heavily. Revenue (TTM) is ~$2.58B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The 2026 outlook was cut, with currency-neutral revenue guided to roughly a 3% decline to modest growth and operating margin trimmed toward 10% to 12%. Whether BIO is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Bio-Rad Laboratories designs and sells laboratory instruments, consumables, and reagents across two segments. Life Science supplies tools for molecular biology, protein analysis, and genomics, including its droplet digital PCR (ddPCR) systems, real-time PCR, electrophoresis, imaging, and process chromatography products. Clinical Diagnostics sells the workflows routine hospital and reference labs rely on: quality-control and data-management systems, blood typing and immunohematology, diabetes monitoring, and specialty assays. Trailing revenue runs around $2.58 billion, and the business is known for recurring consumables attached to a large installed base of instruments. The investment picture is unusual because Bio-Rad also owns roughly 28% of Sartorius, a German bioprocessing and lab-equipment company, and that stake (worth on the order of $5 billion) is valued at nearly the whole of Bio-Rad's own market capitalization. In May 2026 activist Elliott Investment Management disclosed positions in both Bio-Rad and Sartorius, arguing the market gives Bio-Rad little credit for its core operations and pushing to unlock value. Meanwhile the operating business is soft: 2026 guidance was cut, with a conflict in the Middle East hurting the blood-typing diagnostics franchise, even as digital PCR grows at a double-digit clip. The result is a stock where activism, capital allocation, and a volatile equity stake matter as much as instrument sales.
What's the case for buying BIO?
1. Sartorius stake and activist pressure
Bio-Rad's roughly 28% holding in Sartorius is worth close to its entire market value, so movements in that German stock swing Bio-Rad's book value and sentiment heavily. Elliott's May 2026 stake and its stated push to improve the share price and unlock the Sartorius value make capital allocation (monetization, buybacks, or restructuring) a central catalyst. How management responds is arguably the biggest single driver of the equity.
2. Digital PCR and Life Science recovery
Droplet digital PCR remains a differentiated franchise, with instrument revenue up about 24% year over year and the new QX700 platform rolling out ahead of plan on assay enablement. A rebound in biopharma and academic instrument spending, which has been depressed across the tools sector, would lift the higher-margin Life Science segment. Consumables pull-through on a growing installed base supports recurring revenue.
3. Diagnostics stability and margin recovery
Clinical Diagnostics provides a recurring, less cyclical base through blood typing, quality controls, and diabetes monitoring used in routine lab workflows. Management is targeting operating-margin improvement over time through cost discipline and mix, though the 2026 outlook was reset lower. Stabilizing the diagnostics franchise and rebuilding margin is key to the operating-company narrative that activists want the market to credit.
What are the risks to BIO?
The 2026 outlook was cut, with currency-neutral revenue guided to roughly a 3% decline to modest growth and operating margin trimmed toward 10% to 12%. A Middle East conflict reduced first-quarter revenue and remains a headwind for the blood-typing diagnostics business, which drew a meaningful share of the segment from that region. Because the Sartorius stake dwarfs the operating business in value, Bio-Rad's stock and reported results are highly sensitive to that single holding, and reported GAAP earnings can swing to losses on non-cash marks. Instrument demand across life-science tools has been weak, and any activist campaign carries execution and timing uncertainty. Dual-class shares concentrate voting control with the founding family, which can limit outside influence over the pace of change.
How is BIO valued? (as of July 2026)
Snapshot for BIO as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$2.58B
- Q1 2026 revenue: ~$592M
- Q1 2026 non-GAAP EPS: ~$1.89
- Market cap: ~$8.5B
- Sartorius stake (~28%): ~$5B
- 2026 rev guide (cn): ~-3% to +0.5%
At roughly $309 per share and an $8.5 billion market cap, the market values Bio-Rad's Sartorius stake at close to its entire capitalization, implying it assigns little value to the operating business. Trailing earnings are volatile because non-cash marks on the Sartorius holding flow through GAAP results, so headline EPS and P/E can be misleading. The activist thesis rests on that gap between the sum of the parts and the traded value.
How do you decide if BIO is a buy?
Rather than asking whether BIO is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold BIO indirectly through an index or sector ETF before adding more.
For the full picture, see the BIO stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about BIO against your real portfolio and see your actual exposure before deciding.
The bottom line on BIO
The bottom line: Bio-Rad Laboratories's story right now is Sartorius stake and activist pressure, with revenue (ttm) at ~$2.58B. If you believe that narrative continues, the call is about sizing BIO sensibly and checking overlap with what you own; if you doubt it (the risk: the 2026 outlook was cut, with currency-neutral revenue guided to roughly a 3% decline to modest growth and operating margin trimmed toward 10% to 12%.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
More on BIO
- BIO stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- BIO stock forecast (the drivers and risks shaping the outlook)
- Does BIO pay a dividend?
Build a basket around BIO with Walnut
Use Bio-Rad Laboratories as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is BIO a good stock to buy right now?
+
The case for Bio-Rad Laboratories right now is Sartorius stake and activist pressure, with revenue (ttm) at ~$2.58B. If you believe that thesis holds, BIO is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the 2026 outlook was cut, with currency-neutral revenue guided to roughly a 3% decline to modest growth and operating margin trimmed toward 10% to 12%. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Bio-Rad Laboratories do?
+
Bio-Rad Laboratories designs and sells laboratory instruments, consumables, and reagents across two segments.
What are the main risks of BIO?
+
The 2026 outlook was cut, with currency-neutral revenue guided to roughly a 3% decline to modest growth and operating margin trimmed toward 10% to 12%. A Middle East conflict reduced first-quarter revenue and remains a headwind for the blood-typing diagnostics business, which drew a meaningful share of the segment from that region. Because the Sartorius stake dwarfs the operating business in value, Bio-Rad's stock and reported results are highly sensitive to that single holding, and reported GAAP earnings can swing to losses on non-cash marks. Instrument demand across life-science tools has been weak, and any activist campaign carries execution and timing uncertainty. Dual-class shares concentrate voting control with the founding family, which can limit outside influence over the pace of change.
What does Bio-Rad Laboratories do?
+
It makes and sells laboratory instruments, reagents, and consumables through two segments: Life Science (PCR, protein analysis, genomics, chromatography) and Clinical Diagnostics (blood typing, quality controls, diabetes monitoring, and specialty assays used in routine labs).
Why is Bio-Rad's Sartorius stake so important?
+
Bio-Rad owns roughly 28% of Sartorius, a German bioprocessing company, and that stake is worth on the order of $5 billion, close to Bio-Rad's entire market value. As a result, Bio-Rad's book value and stock sentiment move heavily with Sartorius shares.
What is Elliott's involvement with Bio-Rad?
+
In May 2026, activist Elliott Investment Management disclosed stakes in both Bio-Rad and Sartorius, arguing the market undervalues Bio-Rad's operating business and pushing management to improve the share price and unlock value from the Sartorius holding.
How did Bio-Rad perform in Q1 2026?
+
Bio-Rad reported first-quarter 2026 revenue of about $592 million and non-GAAP EPS of roughly $1.89, slightly ahead of some estimates on earnings. Management cut its full-year outlook, citing a Middle East conflict that hurt its blood-typing diagnostics business.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell BIO; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.